title: Does bromocriptine improve glycemic control of obese type-2 diabetics?
abstract: BACKGROUND
  Various oral hypoglycemic agents have already been administered to type-2 diabetic patients to normalize their plasma glucose concentrations but they have not had complete and sustained success. In recent years, bromocriptine has been tried with controversial results. In present study, the effect of bromocriptine on glycemic control was evaluated in obese type-2 diabetic patients.
  
  
  METHODS
  In a double-blind placebo-controlled clinical trial, 40 obese patients with type-2 diabetes (aged 32-70 years) were randomly allocated to the two treatment groups. The first group received bromocriptine (2.5 mg daily) for a total of 3 months. The second group received placebo. They had been uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study. The fasting plasma glucose (FPG) level and glycosylated hemoglobin (HbA1) were measured and body mass index (BMI) was calculated before and 1, 2 and 3 months after treatment.
  
  
  RESULTS
  The FPG level decreased in the bromocriptine-treated group from 10.59 +/- 0.42 to 9.06 +/- 0.41 mmol/l (mean +/- SEM; p < 0.01), whereas in the placebo group it was not changed, 10.69 +/- 0.52 and 10.6 +/- 0.57 mmol/l, respectively. The HbA1 concentration was reduced in the bromocriptine-treated group from 9.9 +/- 0.3 to 9.5 +/-0.2% (p = 0.06), whereas it increased in the placebo-treated group from 10.2 +/- 0.3 to 11.3 +/- 0.6% (p < 0.05). The differences in HbA1 (1.8%, p < 0.01) and FPG (1.55 mmol/l, p < 0.05) levels between the bromocriptine and placebo groups at 3 months were significant. No changes in body weight or BMI occurred during the study in either placebo- or bromocriptine-treated group.
  
  
  CONCLUSIONS
  The data further support the contention that bromocriptine improves glycemic control in obese type-2 diabetic patients, although the mechanism of action remains to be determined.
authors.affiliation: Isfahan Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. aminorroaya@med.mui.ac.ir
authors.forename: Ashraf
authors.initials: A
authors.lastname: Aminorroaya
authors.forename: Mohsen
authors.initials: M
authors.lastname: Janghorbani
authors.forename: Majid
authors.initials: M
authors.lastname: Ramezani
authors.forename: Sassan
authors.initials: S
authors.lastname: Haghighi
authors.forename: Massoud
authors.initials: M
authors.lastname: Amini
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D001971:Bromocriptine / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D005905:Glyburide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications*; D010919:Placebos
chemical_list: D001786:Blood Glucose; D001971:Bromocriptine; D018491:Dopamine Agonists; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010919:Placebos